Mitochondrial injury and cognitive function in HIV infection and methamphetamine use

AIDS

Volumn 30, Issue 6, 2016, Pages 839-847

  Var, Susanna R ^a   Day, Tyler R C ^a   Vitomirov, Andrej ^a   Smith, Davey M ^a,b   Soontornniyomkij, Virawudh ^a   Moore, David J ^a   Achim, Cristian L ^a   Mehta, Sanjay R ^a,b   Pérez Santiago, Josué ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

common deletion; droplet digital polymerase chain reaction; Global Deficit Score; HIV; methamphetamine; mitochondrial DNA; mitochondrial injury; neurocognitive impairment

Indexed keywords

METHAMPHETAMINE; MITOCHONDRIAL DNA; CENTRAL STIMULANT AGENT;

ADULT; AGE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GLOBAL DEFICIT SCORE; GRAY MATTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; METHAMPHETAMINE DEPENDENCE; MIDDLE AGED; MITOCHONDRIAL INJURY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCORING SYSTEM; WHITE MATTER; BRAIN; CHEMICALLY INDUCED; COGNITION; COHORT ANALYSIS; COMPLICATION; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG DEPENDENCE; DRUG EFFECTS; GENETICS; MALE; MITOCHONDRION; PATHOLOGY;

ADULT; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; COHORT STUDIES; DNA, MITOCHONDRIAL; HIV INFECTIONS; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; MITOCHONDRIA; NEUROCOGNITIVE DISORDERS; POLYMERASE CHAIN REACTION; SUBSTANCE-RELATED DISORDERS;

EID: 84960408970     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001027     Document Type: Article

References (51)

1. Wallace DC A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359-407.
2. Zhang J, Block ER, Patel JM. Down-regulation of mitochondrial cytochrome c oxidase in senescent porcine pulmonary artery endothelial cells. Mech Ageing Dev 2002; 123: 1363-1374.
3. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimers disease. J Neurochem 2005; 93: 953-962.
4. Mamdani F, Rollins B, Morgan L, Sequeira PA, Vawter MP. The somatic common deletion in mitochondrial DNA is decreased in schizophrenia. Schizophr Res 2014; 159: 370-375.
5. Chen B, Zhong Y, Peng W, Sun Y, Hu YJ, Yang Y, et al. Increased mitochondrial DNA damage and decreased base excision repair in the auditory cortex of D-galactose-induced aging rats. Mol Biol Rep 2011; 38: 3635-3642.
6. Trifunovic A, Larsson NG. Mitochondrial dysfunction as a cause of ageing. J Intern Med 2008; 263: 167-178.
7. Perfeito R, Cunha-Oliveira T, Rego AC. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med 2012; 53: 1791-1806.
8. Langford D, Grigorian A, Hurford R, Adame A, Crews L, Masliah E. The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J Neurovirol 2004; 10: 327-337.
9. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-Associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17: 3-16.
10. Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, Koyanagi Y. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 2008; 82: 2528-2542.
11. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-Associated neurocognitive disorders pathogenesis. Curr Opin Neurol 2011; 24: 275-283.
12. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev 2009; 60: 379-407.
13. Shah A, Kumar S, Simon SD, Singh DP, Kumar A. HIV gp120-And methamphetamine-mediated oxidative stress induces astrocyte apoptosis via cytochrome P450 2E1. Cell Death Dis 2013; 4: e850.
14. Semple SJ, Patterson TL, Grant I. Motivations associated with methamphetamine use among HIVR men who have sex with men. J Subst Abuse Treat 2002; 22: 149-156.
15. Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 2004; 38: 890-894.
16. Halkitis PN, Fischgrund BN, Parsons JT. Explanations for methamphetamine use among gay and bisexual men in New York City. Subst Use Misuse 2005; 40: 1331-1345.
17. Shoptaw S. Methamphetamine use in urban gay and bisexual populations. Top HIV Med 2006; 14: 84-87.
18. Mantri CK, Mantri JV, Pandhare J, Dash C. Methamphetamine inhibits HIV-1 replication in CD4R T cells by modulating anti-HIV-1 miRNA expression. Am J Pathol 2014; 184: 92-100.
19. Potula R, Hawkins BJ, Cenna JM, Fan S, Dykstra H, Ramirez SH, et al. Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol 2010; 185: 2867-2876.
20. Nair MP, Saiyed ZM. Effect of methamphetamine on expression of HIV coreceptors and CC-chemokines by dendritic cells. Life Sci 2011; 88: 987-994.
21. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008; 172: 1617-1624.
22. Perez-Santiago J, Schrier RD, de Oliveira MF, Gianella S, Var SR, Day TR, et al. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. J Neurovirol 2015[Epub ahead of print
23. Sung YH, Yurgelun-Todd DA, Shi XF, Kondo DG, Lundberg KJ, McGlade EC, et al. Decreased frontal lobe phosphocreatine levels in methamphetamine users. Drug Alcohol Depend 2013; 129: 102-109.
24. Morales AM, Lee B, Hellemann G, ONeill J, London ED. Graymatter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine. Drug Alcohol Depend 2012; 125: 230-238.
25. Venkateshappa C, Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimers disease. Neurochem Res 2012; 37: 1601-1614.
26. Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinsons disease. Biochim Biophys Acta 2010; 1802: 29-44.
27. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H. Mono- And double-mutant mouse models of Parkinsons disease display severe mitochondrial damage. Hum Mol Genet 2007; 16: 2377-2393.
28. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 2012; 26: 894-908.
29. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004; 26: 307-319.
30. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8: e55943.
31. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27: 1387-1395.
32. Clifford DB, Ances BM. HIV-Associated neurocognitive disorder. Lancet Infect Dis 2013; 13: 976-986.
33. Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 2012; 60: 234-243.
34. Kuningas M, Estrada K, Hsu YH, Nandakumar K, Uitterlinden AG, Lunetta KL, et al. Large common deletions associate with mortality at old age. Hum Mol Genet 2011; 20: 4290-4296.
35. Zheng Y, Luo X, Zhu J, Zhang X, Zhu Y, Cheng H, et al. Mitochondrial DNA 4977 bp deletion is a common phenomenon in hair and increases with age. Bosn J Basic Med Sci 2012; 12: 187-192.
36. Liedhegner EAS, Gao XH, Mieyal JJ. Mechanisms of altered redox regulation in neurodegenerative diseases-focus on S-glutathionylation. Antioxid Redox Signal 2012; 16: 543-566.
37. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008; 112: 1912-1922.
38. Domercq M, Sanchez-Gomez MV, Areso P, Matute C. Expression of glutamate transporters in rat optic nerve oligodendrocytes. Eur J Neurosci 1999; 11: 2226-2236.
39. Matute C, Alberdi E, Domercq M, Sanchez-Gomez MV, Perez-Samartin A, Rodriguez-Antiguedad A, et al. Excitotoxic damage to white matter. J Anat 2007; 210: 693-702.
40. Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed 2008; 93: F153-F161.
41. Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia 2014; 62: 1816-1830.
42. Ziskin JL, Nishiyama A, Rubio M, Fukaya M, Bergles DE. Vesicular release of glutamate from unmyelinated axons in white matter. Nat Neurosci 2007; 10: 321-330.
43. Cadet JL, Ali SF, Rothman RB, Epstein CJ. Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Mol Neurobiol 1995; 11: 155-163.
44. Chu CT. Diversity in the regulation of autophagy and mitophagy: lessons from Parkinsons disease. Parkinsons Dis 2011; 2011: 789431.
45. Rau CR, Hein K, Sattler MB, Kretzschmar B, Hillgruber C, McRae BL, et al. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. Am J Pathol 2011; 178: 1770-1781.
46. Zou S, Li L, Pei L, Vukusic B, Van Tol HH, Lee FJ, et al. Proteinprotein coupling/uncoupling enables dopamine D2 receptor regulation of AMPA receptor-mediated excitotoxicity. J Neurosci 2005; 25: 4385-4395.
47. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Kanki R, et al. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res 2002; 70: 274-282.
48. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 2007; 11: 185-194.
49. Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res 2014; 12: 13-21.
50. Mandas A, Iorio EL, Congiu MG, Balestrieri C, Mereu A, Cau D, et al.Oxidative imbalance in HIV-1 infected patients treatedwith antiretroviral therapy. J Biomed Biotechnol 2009; 2009: 749575.
51. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, et al. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIVR) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005; 11: 356-364.